Result of AGM

Kromek Group PLC

23 October 2026

 

23 October 2026

Kromek Group plc 

(“Kromek” or the “Group”) 

Result of AGM

Kromek (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that at its annual general meeting (“AGM”), held earlier today, all resolutions were duly passed.

Details of the proxy voting results, which should be read alongside the Notice of AGM, are below:

Resolution	Votes for*		Votes against		Votes withheld	Total proxy votes
	No. of votes	% of votes cast**	No. of votes	% of votes cast**	No. of votes
1	205,022,327	99.61	796,215	0.39	2,843,040	208,661,582
2	204,417,129	99.10	1,860,846	0.90	2,383,607	208,661,582
3	203,475,996	98.64	2,804,385	1.36	2,381,201	208,661,582
4	203,745,706	98.67	2,751,896	1.33	2,163,980	208,661,582
5	202,889,975	98.37	3,355,583	1.63	2,416,024	208,661,582
6	201,047,402	97.83	4,462,081	2.17	3,152,099	208,661,582
7	201,576,283	98.09	3,920,647	1.91	3,164,652	208,661,582
8	205,402,636	99.37	1,300,513	0.63	1,958,433	208,661,582
9	202,294,735	98.93	2,194,665	1.07	4,172,182	208,661,582

*Includes discretionary votes

**Excludes withheld votes

Enquiries 

Investor questions on this announcement
We encourage all investors to share questions on this announcement via our investor hub	https://investors.kromek.com/link/r8XkWr
Kromek Group plc
Arnab Basu, CEO  Claire Burgess, CFO	[phone]
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker – Corporate Finance  Andrew Burdis – ECM Michael Johnson – Sales	[phone]
Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury	[phone]

Engage with the Kromek management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our interactive investor
hub here: https://investors.kromek.com/

Subscribe to our news alert service: https://investors.kromek.com/auth/signup

Kromek Group plc 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

 

END